Spots Global Cancer Trial Database for Genetic Mutations in Blood and Tissue Samples in Predicting Response to Treatment in Patients With Locally Advanced Rectal Cancer Undergoing Chemoradiation

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Genetic Mutations in Blood and Tissue Samples in Predicting Response to Treatment in Patients With Locally Advanced Rectal Cancer Undergoing Chemoradiation

Official Title: Assessing Intratumoral Heterogeneity and Chemoradiation Response in Locally Advanced Rectal Cancer Utilizing Sequencing and PET/CT

Study ID: NCT02132858

Conditions

Mucinous Adenocarcinoma of the Rectum

Recurrent Rectal Cancer

Signet Ring Adenocarcinoma of the Rectum

Stage IIA Rectal Cancer

Stage IIB Rectal Cancer

Stage IIC Rectal Cancer

Stage IIIA Rectal Cancer

Stage IIIB Rectal Cancer

Stage IIIC Rectal Cancer

Interventions

cytology specimen collection procedure

laboratory biomarker analysis

Study Description

Brief Summary: This research trial studies genetic mutations in blood and tissue samples to see if they can be used to predict treatment response in patients with locally advanced rectal cancer undergoing chemoradiation. Studying samples of blood and tumor tissue in the laboratory from patients with cancer may help doctors learn more about genetic mutations or changes that occur in deoxyribonucleic acid (DNA) and help doctors understand how patients respond to treatment.

Detailed Description: PRIMARY OBJECTIVES: I. To evaluate the tumor-specific mutation(s) detected using the CancerCode™ mutation panel as a predictor of pathologic response to chemoradiation for patients with rectal adenocarcinoma undergoing chemoradiation. SECONDARY OBJECTIVES: I. To assess the feasibility of utilizing biopsy specimens from locally advanced rectal adenocarcinoma to perform CancerCode™ mutation panel genetic testing. II. To assess disease-free survival (DFS) and overall survival (OS) of patients treated on study. III. To collect pilot data regarding the clonal heterogeneity of rectal adenocarcinoma, and the relationship of this heterogeneity with treatment response. IV. To evaluate the treatment response utilizing multiple fludeoxyglucose F 18-positron emission tomography (FDG-PET) parameters including heterogeneity and textural features as an exploratory study. OUTLINE: Patients undergo collection of blood and tissue samples for analysis via sequencing. After completion of study, patients are followed up every 3 months for 3 years.